Mega deal worth Rs 271 crore: Sun Pharma is going to buy Innovicare, the giant stock will be in focus on Monday – ..

This weekend, news of a very big corporate deal has come out from the pharma sector, the direct impact of which will be seen as soon as the stock market opens on Monday, June 22. Taking a strategic step, Sun Pharmaceutical Industries, one of the largest pharma companies in the country, has officially announced the purchase of 100% stake in about 12 year old company Innovcare Lifesciences. Sun Pharma has shared the details of this agreement in a stock exchange filing on the evening of June 20. This entire deal has been finalized for ₹271.2 crore (about $2.873 crore), after which market experts are expecting a sharp movement in the shares of Sun Pharma on Monday.

Company will strengthen product portfolio, cash deal to be completed by July 31

According to the information given to the stock exchange, Sun Pharma is going to acquire all the outstanding shares (total shares present in the market) of Innovicare Lifesciences. The company is confident that the entire takeover process will be completed on or before July 31, 2026. The special thing is that this entire deal will be settled completely as a ‘cash deal’.

Sun Pharma has described this acquisition as a very important and strategic step towards further diversifying and strengthening its product portfolio. If we talk about Innovicare Lifesciences, this company was started on 21 July 2014. The company is active in the rapidly growing nutraceutical (nutritional products) and cosmeceutical (products with cosmetic and medicinal properties) sectors along with pharmaceutical drugs in the Indian market. Its entire business network is strongly spread in India. The company’s performance has also improved on the financial front; During the financial year 2025-26, the operational revenue of the company has increased from ₹ 86.09 crore to ₹ 94.06 crore on an annual basis.

Price is 4% below record high, gave excellent returns in last 8 months

Just before the announcement of this deal, i.e. on Friday, June 19, the last trading day of the week, Sun Pharma’s shares closed at ₹ 1837.15 on BSE with a slight rise of 0.72%.

For investors, let us analyze the performance of Sun Pharma in the last one year:

• One Year Low (52-Week Low): Last year, the stock was at its lowest level of ₹1547.25 on September 26, 2025.

• One Year High (52-Week High): Showing a spectacular recovery from this low, the stock gained 23.91% in just 8 months and reached an all-time high of ₹1917.15 on May 19, 2026.

• Current Status: However, after hitting record highs, the shares have seen some profit booking and the current price is trading about 4% below its life-time high. In such a situation, the movement on Monday can again take this stock towards a new record.